AAAAAA
Results: 1-25/29
Authors:
GARNETT WR
Citation: Wr. Garnett, IS CURING PEPTIC-ULCER DISEASE AN OXYMORON - A FOCUS ON HELICOBACTER-PYLORI, American journal of managed care, 4(4), 1998, pp. 281-296
Authors:
GARNETT WR
Citation: Wr. Garnett, CONSIDERATIONS FOR LONG-TERM USE OF PROTON-PUMP INHIBITORS, American journal of health-system pharmacy, 55(21), 1998, pp. 2268-2279
Authors:
PELLOCK JM
MOSHE SL
DODSON WE
SHINNAR S
MORTON LD
WHELESS JW
TERNDRUP TE
BEBIN EM
GARNETT WR
JAGODA A
GRAVES N
Citation: Jm. Pellock et al., MANAGEMENT OF ACUTE SEIZURES IN CHILDREN - DISCUSSION, Journal of child neurology, 13, 1998, pp. 30-32
Authors:
ADAMS MH
POYNOR WJ
GARNETT WR
KARNES HT
FERRY JJ
RYAN KK
SARKAR MA
Citation: Mh. Adams et al., PHARMACOKINETICS OF MINOXIDIL IN PATIENTS WITH CIRRHOSIS AND HEALTHY-VOLUNTEERS, Biopharmaceutics & drug disposition, 19(8), 1998, pp. 501-515
Authors:
GARNETT WR
HOGAN RE
RAK IW
THADANI VM
CEREGHINO JJ
BROWN LM
ZHANG YX
BELENDIUK GW
Citation: Wr. Garnett et al., LONG-TERM SAFETY, EFFICACY, AND QUALITY-OF-LIFE DATA FOR CARBATROL(R)(CARBAMAZEPINE EXTENDED-RELEASE CAPSULES) IN COMPLEX PARTIAL SEIZURES, Neurology, 50(4), 1998, pp. 2048-2048
Authors:
HOGAN RE
MIRZA WU
RAK IW
THADANI VM
CEREGHINO JJ
GARNETT WR
BROWN LM
ZHANG YX
BELENDIUK GW
Citation: Re. Hogan et al., 6 MONTH SAFETY, EFFICACY AND QUALITY-OF-LIFE DATA FOR CARBATROL(R) (CARBAMAZEPINE EXTENDED-RELEASE CAPSULES) IN COMPLEX PARTIAL SEIZURES, Neurology, 50(4), 1998, pp. 64001-64001
Authors:
GARNETT WR
LEVY B
MCLEAN AM
ZHANG YX
COUCH RA
RUDNIC EM
PELLOCK JM
BELENDIUK GW
Citation: Wr. Garnett et al., PHARMACOKINETIC EVALUATION OF TWICE-DAILY EXTENDED-RELEASE CARBAMAZEPINE (CBZ) AND 4-TIMES-DAILY IMMEDIATE-RELEASE CBZ IN PATIENTS WITH EPILEPSY, Epilepsia, 39(3), 1998, pp. 274-279
Authors:
GARNETT WR
Citation: Wr. Garnett, THE RATIONALE FOR TREATING HYPERCHOLESTEROLEMIA, American journal of managed care, 3, 1997, pp. 12-22
Authors:
RAMSAY RE
WILDER BJ
UTHMAN BM
GARNETT WR
PELLOCK JM
BARKLEY GL
LEPPIK IE
KNAPP LE
Citation: Re. Ramsay et al., INTRAMUSCULAR FOSPHENYTOIN (CEREBYX(R)) IN PATIENTS REQUIRING A LOADING DOSE OF PHENYTOIN, Epilepsy research, 28(3), 1997, pp. 181-187
Authors:
GARNETT WR
Citation: Wr. Garnett, LAMOTRIGINE - PHARMACOKINETICS, Journal of child neurology, 12, 1997, pp. 10-15
Authors:
GARNETT WR
GARABEDIANRUFFALO SM
Citation: Wr. Garnett et Sm. Garabedianruffalo, IDENTIFICATION, DIAGNOSIS, AND TREATMENT OF ACID-RELATED DISEASES IN THE ELDERLY - IMPLICATIONS FOR LONG-TERM-CARE, Pharmacotherapy, 17(5), 1997, pp. 938-958
Authors:
GARNETT WR
Citation: Wr. Garnett, LANSOPRAZOLE - A PROTON PUMP INHIBITOR, The Annals of pharmacotherapy, 30(12), 1996, pp. 1425-1436
Authors:
VACHHARAJANI NN
SHYU WC
GARNETT WR
MORGENTHIEN EA
BARBHAIYA RH
Citation: Nn. Vachharajani et al., THE ABSOLUTE BIOAVAILABILITY AND PHARMACOKINETICS OF BUTORPHANOL NASAL SPRAY IN PATIENTS WITH HEPATIC IMPAIRMENT, Clinical pharmacology and therapeutics, 60(3), 1996, pp. 283-294
Authors:
SLATTUM PW
BRIGGS GC
HAWLEY JM
GARNETT WR
VENITZ J
Citation: Pw. Slattum et al., PHARMACOKINETICS (PK) AND CNS PHARMACODYNAMICS (PD) OF DIPHENHYDRAMINE (DIP), Clinical pharmacology and therapeutics, 59(2), 1996, pp. 78-78
Authors:
WILDER BJ
CAMPBELL K
RAMSAY RE
GARNETT WR
PELLOCK JM
HENKIN SA
KUGLER AR
Citation: Bj. Wilder et al., SAFETY AND TOLERANCE OF MULTIPLE DOSES OF INTRAMUSCULAR FOSPHENYTOIN SUBSTITUTED FOR ORAL PHENYTOIN IN EPILEPSY OR NEUROSURGERY, Archives of neurology, 53(8), 1996, pp. 764-768
Authors:
GARNETT WR
Citation: Wr. Garnett, A REVIEW OF CURRENT CLINICAL FINDINGS WITH FLUVASTATIN, The American journal of cardiology, 78, 1996, pp. 20-25
Authors:
GARNETT WR
Citation: Wr. Garnett, UTILIZATION OF THE BIOTRACK-516 SYSTEM IN POINT-OF-CARE THERAPEUTIC DRUG-MONITORING, Journal of clinical ligand assay, 18(1), 1995, pp. 43-48
Authors:
GARNETT WR
Citation: Wr. Garnett, INTERACTIONS WITH HYDROXYMETHYLGLUTARYL-COENZYME-A REDUCTASE INHIBITORS, American journal of health-system pharmacy, 52(15), 1995, pp. 1639-1645
Authors:
GARNETT WR
Citation: Wr. Garnett, NEW OPPORTUNITIES FOR THE TREATMENT OF EPILEPSY, American journal of health-system pharmacy, 52(1), 1995, pp. 88-91
Authors:
GIDAL BE
GARNETT WR
Citation: Be. Gidal et Wr. Garnett, PERSPECTIVE ON LAMOTRIGINE, The Annals of pharmacotherapy, 29(2), 1995, pp. 191-192
Authors:
TEAGUE AC
GARNETT WR
BRIGGS GC
STANLEY HR
Citation: Ac. Teague et al., THE EFFECT OF AGE AND EVERYDAY EXERCISE ON STEADY-STATE PLASMA DIGOXIN CONCENTRATIONS, Pharmacotherapy, 15(4), 1995, pp. 502-508
Authors:
REECE PA
GARNETT WR
ROCK WL
TAYLOR JR
UNDERWOOD B
SEDMAN AJ
RAJAGOPALAN R
Citation: Pa. Reece et al., LACK OF EFFECT OF TACRINE ADMINISTRATION ON THE ANTICOAGULANT ACTIVITY OF WARFARIN, Journal of clinical pharmacology, 35(5), 1995, pp. 526-528
Authors:
GARNETT WR
KUGLER AR
OHARA KA
DRISCOLL SM
PELLOCK JM
Citation: Wr. Garnett et al., PHARMACOKINETICS OF FOSPHENYTOIN AND PHENYTOIN FOLLOWING INTRAMUSCULAR ADMINISTRATION OF FOSPHENYTOIN SUBSTITUTED FOR ORAL PHENYTOIN IN EPILEPTIC PATIENTS, Neurology, 45(4), 1995, pp. 248-248
Authors:
RAMSAY RE
BARKLEY GL
GARNETT WR
PELLOCK JM
LEPPIK IE
WILDER BJ
UTHMAN B
Citation: Re. Ramsay et al., SAFETY AND TOLERANCE OF INTRAMUSCULAR FOSPHENYTOIN (CEREBYX(R)) IN PATIENTS REQUIRING A LOADING DOSE OF PHENYTOIN, Neurology, 45(4), 1995, pp. 249-249
Authors:
GARNETT WR
Citation: Wr. Garnett, FLUVASTATIN COST CONSIDERATIONS, The Annals of pharmacotherapy, 28(9), 1994, pp. 1111-1112